metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1	-	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus BSC
	durvalumab plus tremelimumab vs. BSC	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
versus regorafenib
	atezolizumab alone vs. regorafenib	1	889 [-470; 2248] /10000 65/90 vs. 57/90	1889 [475; 3303] /10000 61/90 vs. 44/90	-
	atezolizumab plus cometinib vs. regorafenib	1	497 [-705; 1700] /10000 125/183 vs. 57/90	1177 [-75; 2429] /10000 111/183 vs. 44/90	-